For adults with presumed early-stage endometrial cancer, what are the benefits and risks of performing pelvic lymphadenectomy at the time of standard surgery (typically hysterectomy and bilateral salpingo-oophorectomy) versus standard surgery alone?

Summary

This Cochrane Clinical Answers review synthesises evidence on the role of pelvic lymphadenectomy in the surgical management of early-stage endometrial cancer, weighing potential staging and oncological benefits against surgical morbidity and patient harm. As suggested by the title, the analysis appears to address whether routine lymphadenectomy at the time of standard surgery offers meaningful clinical advantage or additional risk in this population. The review contributes to evidence-based guidance on surgical decision-making in early endometrial cancer.

UK applicability

Findings are applicable to UK gynaecological oncology practice and National Institute for Health and Care Excellence (NICE) guidance on endometrial cancer surgical management. The review's conclusions may inform consultant decision-making and patient counselling regarding extent of surgery in NHS settings.

Key measures

Likely oncological outcomes (recurrence, survival), surgical morbidity (infection, bleeding, lymphoedema), operative time, hospital stay, and quality-of-life measures.

Outcomes reported

The study examined clinical outcomes (oncological and morbidity-related) associated with pelvic lymphadenectomy as an adjunct to standard hysterectomy and bilateral salpingo-oophorectomy in adults with presumed early-stage endometrial cancer.

Topic tags